Table I.
Characteristics of randomized controlled trials.
| Study (year) | Gestation age (weeks) | N | Inclusion criteria | Intervention | Outcomes | (Refs.) |
|---|---|---|---|---|---|---|
| Ayala et al (2013) | ≤16 | 350 | Pregnant women with higher risk for gestational hypertension or preeclampsia | ASA 100 mg/d vs. placebo | PE; preterm birth; IUGR; stillbirth; newborn weight; Apgar score; gestational hypertension; postpartum hemorrhage | (27) |
| Bakhti and Vaiman (2011) | 8–10 | 164 | Women without previous vasculo-renal pathology | ASA 100 mg/d vs. no treatment | Preterm PE; PE; IUGR; gestation hypertension; postpartum hemorrhage; stillbirth; preterm birth; newborn weight | (28) |
| Benigni et al (1989) | 12 | 33 | Women with hypertension or previous obstetrical history: Fetal death, severe IUGR, early onset of preeclampsia | ASA 60 mg/d vs. placebo | PE; gestational hypertension; preterm birth; IUGR; perinatal death; newborn weight | (29) |
| Caritis et al (1998) | 13–16 | 523 | Women with diabetes mellitus, chronic hypertension or a history of PE | ASA 60 mg/d vs. placebo | PE; IUGR; newborn weight. | (30) |
| Chiaffarino et al (2004) | <14 | 35 | Women with chronic hypertension, history of severe pre-eclampsia or eclampsia or IUGR or intrauterine fetal death | ASA 100 mg/d vs. no treatment | PE; gestational hypertension; abortion; birth weight | (31) |
| Ebrashy et al (2005) | 14–16 | 139 | A high-risk factor for preeclampsia or IUGR, including previous history of the disease, essential hypertension, family history of or underlying vascular disorder, maternal age <20 or >40 years, and gestational diabetes mellitus | ASA 75 mg/d vs. no treatment | Preterm PE; PE; IUGR; preterm birth; apgar score; maternal hemorrhage; newborn weight | (32) |
| Hermida et al (1997) | 12–16 | 100 | Women with risk factors of pre-eclampsia: Family or own history of gestational hypertension or PE, chronic HT, cardiovascular or endocrine problem, bleeding or endocrine disease | ASA 100 mg/d vs. placebo | PE; gestational hypertension; preterm birth; IUGR; perinatal death; birth weight | (33) |
| Rolnik et al (2017) | 11–14 | 1,620 | Women with high risk high risk (>1 in 100) for preterm preeclampsia according to the screening algorithm | ASA 150 mg/d vs. placebo | Preterm PE; PE; gestational hypertension; preterm birth; stillbirth; abruption; SGA | (7) |
| Vainio et al (2002) | 12–14 | 86 | Women considered to be at high risk of preeclampsia or intrauterine growth retardation were screened by transvaginal Doppler ultrasound | ASA 0.5 mg/kg/d vs. placebo | Preterm PE; PE; gestational hypertension; preterm birth; stillbirth; abruption; SGA | (34) |
| Villa et al (2013) | 12–13 | Women with risk factors for pre-eclampsia or abnormal uterine artery Doppler velocimetry | ASA 100 mg/d vs. placebo | Preterm PE; PE; gestational hypertension; newborn birthweight; Apgar score | (35) |
ASA, acetylsalicylic acid; PE, preeclampsia; IUGR, intrauterine growth retardation; SGA, small for gestation age infant; d, day.